An open label trial evaluating the pharmacokinetics and safety of an intravenously administered single dose of Feramyl 200 mg, 500 mg or 1500 mg vs. Ferinject 500 mg in patients suffering from anaemia following cardiac surgery

Trial Profile

An open label trial evaluating the pharmacokinetics and safety of an intravenously administered single dose of Feramyl 200 mg, 500 mg or 1500 mg vs. Ferinject 500 mg in patients suffering from anaemia following cardiac surgery

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Hydroxyethyl starch (Primary) ; Ferric carboxymaltose
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors Serumwerk Bernburg
  • Most Recent Events

    • 26 Feb 2017 Status changed from recruiting to completed.
    • 10 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top